Exelixis
EXEL
#1726
Rank
โ‚น1.203 T
Marketcap
โ‚น4,787
Share price
-0.34%
Change (1 day)
30.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น280.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น299.78. In 2025 the company made an earnings per share (EPS) of โ‚น276.80.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น280.561.36%
2025โ‚น276.80
2023โ‚น62.5714.61%
2022โ‚น54.59-22.97%
2021โ‚น70.88100%
2020โ‚น35.44-65.09%
2019โ‚น101.52-53.91%
2018โ‚น220.29333.96%
2017โ‚น50.76-260.61%
2016-โ‚น31.61-58.75%
2015-โ‚น76.62-42.45%
2014-โ‚น133.135.3%
2013-โ‚น126.43

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น836.75 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น125.47-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,387 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น245.16-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น340.71 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น340.97 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น372.22 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น351.50-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น80.45-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA